Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventana submits FDA filing for HER2 theranostic:

This article was originally published in Clinica

Executive Summary

Ventana Medical Systems has filed for US approval of its novel theranostic for the breast cancer drug Herceptin (trastuzumab). The test, called the Inform HER2 SISH (silver in situ hybridisation) DNA probe assay, can identify patients suitable for Herceptin treatment in just six hours - half the time of current tests, which are based on FISH (fluorescence in situ hybridisation). The test identifies patients with amplified levels of the HER2 biomarker gene. The fully automated test will also be cheaper than standard tests, and allows the pathologist to archive slides, enabling the possibility of re-examination, claimed the Tucson, Arizona firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel